[vc_row][vc_column width=”1/1″][mp_block_1 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”4″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_4 category_display=”root” post_sort=”date” post_limit=”4″ post_offset=”7″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_widget_sidebar sidebar_id=”content-ad-1″ el_class=”content-ad”][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_6 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”11″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_6 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”14″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_widget_sidebar sidebar_id=”content-ad-2″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_6 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”18″][/vc_column][/vc_row]
Home
Recent Posts
- McQuade Center, Sentinel Oncology Working on New Therapy
- New Institute Aims to Leave No Rare Disease Patient Behind
- Group Focuses on Rare Disease Clinical Trial Participation
- ‘Running for Rare’: NORD a Charity Partner of 2021 NYC Marathon
- Anavex2-73 Shows Efficacy in Fragile X Mouse Study, Phase 2/3 Trial Planned
- CDC Funds Five-year Study to Better Define Fragile X Natural History
- ‘Not Alone in the Dark’: New Guide for, by Caregivers of Children With Rare Diseases
- EU Orphan Drug Status Sought for Nova Therapy Using Hallucinogenic Psilocybin
- Register Now for Global Genes’ RARE Patient Advocacy Summit
- NORD Rare Disease Summit, Online Oct. 18-19, Open for Registration